SCHEMBL257291

SCHEMBL257291

COc1ccc(-c2c(C)nn3c(-c4cccc(C(F)(F)F)c4)cc(N4CCC[C@H]4CO)nc23)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.47
MAPK1 P28482 1/20 0.46
CYP1A2 P05177 1/20 0.44
SPHK2 Q9NRA0 1/20 0.44
SPHK1 Q9NYA1 1/20 0.44
MEN1 O00255 1/20 0.43
ALDH1A1 P00352 1/20 0.43
KMT2A Q03164 1/20 0.43
ITGB2 P05107 1/20 0.41
ICAM1 P05362 1/20 0.41
ITGAL P20701 1/20 0.41
PLAT P00750 1/20 0.39
LMNA P02545 1/20 0.38
POLB P06746 1/20 0.38
XBP1 P17861 1/20 0.38
HTT P42858 1/20 0.38
BLM P54132 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
TRPV1 Q8NER1 1/20 0.38
TDP1 Q9NUW8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15020747 1.00 MAPT (0.47) MAPTMAPK1CYP1A2SPHK2SPHK1
SCHEMBL15020591 0.93 MEN1 (0.46) MAPTMAPK1SPHK2SPHK1MEN1
SCHEMBL15020901 0.92 SPHK2 (0.43) MAPTMAPK1CYP1A2SPHK2SPHK1
SCHEMBL15020944 0.92 SPHK2 (0.44) MAPTMAPK1SPHK2SPHK1MEN1
SCHEMBL15020733 0.92 MAPT (0.45) MAPTMAPK1CYP1A2SPHK2SPHK1
SCHEMBL15021376 0.92 KMT2A (0.45) MAPTMAPK1SPHK2SPHK1MEN1
SCHEMBL256817 0.92 KMT2A (0.45) MAPTMAPK1SPHK2SPHK1MEN1
SCHEMBL15042205 0.92 MEN1 (0.46) MAPTMAPK1SPHK2SPHK1MEN1
SCHEMBL15020808 0.91 ALDH1A1 (0.44) MAPTMAPK1SPHK2SPHK1MEN1
SCHEMBL15020701 0.91 KMT2A (0.44) MAPTSPHK2SPHK1MEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 US disclosed
US-8975264-B2 Compound acting as a cannabinoid receptor-1 inhibitor AMOREPACIFIC CORPORATION (KR) 2015-03-10 US disclosed
EP-2617723-A2 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR Amorepacific Corporation (KR) 2013-07-24 EP disclosed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 US disclosed
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR AMOREPACIFIC CORPORATION (KR) 2013-06-20 US disclosed
WO-2012030170-A2 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR (주)아모레퍼시픽 (KR) 2012-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130158025-A1 NOVEL COMPOUND ACTING AS A CANNABINOID RECEPTOR-1 INHIBITOR CNR1, CNR2, GPR18 MAPT 2617/4885MAPK1 519/4885CYP1A2 2839/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.